LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PD0325901 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1727 | 3694 | 0.4676 | 0.1130 |
| SK-BR-3 | PD0325901 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1787 | 3694 | 0.4838 | 0.1401 |
| SK-BR-3 | PD173074 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1980 | 3694 | 0.5360 | 0.2270 |
| SK-BR-3 | PD184352 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 2732 | 3694 | 0.7396 | 0.5661 |
| SK-BR-3 | Pelitinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1088 | 3694 | 0.2947 | -0.1750 |
| SK-BR-3 | PF431396 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1383 | 3694 | 0.3746 | -0.0420 |
| SK-BR-3 | PF477736 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1410 | 3694 | 0.3817 | -0.0301 |
| SK-BR-3 | PF562271 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1246 | 3694 | 0.3375 | -0.1038 |
| SK-BR-3 | PHA-665752 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 928 | 3694 | 0.2514 | -0.2472 |
| SK-BR-3 | PHA-793887 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1049 | 3694 | 0.2840 | -0.1929 |
| SK-BR-3 | PI103 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1389 | 3694 | 0.3761 | -0.0394 |
| SK-BR-3 | PLX-4720 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 2004 | 3694 | 0.5427 | 0.2381 |
| SK-BR-3 | QL-X-138 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1220 | 3694 | 0.3304 | -0.1156 |
| SK-BR-3 | QL-XII-47 | 10.0 | uM | LJP6 | 72 | hr | 1476 | 659 | 3694 | 0.1786 | -0.3685 |
| SK-BR-3 | Radicicol | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1213 | 3694 | 0.3286 | -0.1186 |
| SK-BR-3 | Radicicol | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1124 | 3694 | 0.3043 | -0.1591 |
| SK-BR-3 | Seliciclib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1413 | 3694 | 0.3825 | -0.0287 |
| SK-BR-3 | Ruxolitinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 2785 | 3694 | 0.7540 | 0.5902 |
| SK-BR-3 | XL147 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 2821 | 3694 | 0.7638 | 0.6064 |
| SK-BR-3 | Saracatinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1968 | 3694 | 0.5329 | 0.2219 |
| SK-BR-3 | Selumetinib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 3522 | 3694 | 0.9534 | 0.9224 |
| SK-BR-3 | Sirolimus | 10.0 | uM | LJP6 | 72 | hr | 1476 | 2203 | 3694 | 0.5964 | 0.3276 |
| SK-BR-3 | Sorafenib | 10.0 | uM | LJP6 | 72 | hr | 1476 | 1730 | 3694 | 0.4685 | 0.1145 |
| SK-BR-3 | SU11274 | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1469 | 3694 | 0.3977 | -0.0035 |
| SK-BR-3 | Fedratinib | 10.0 | uM | LJP5 | 72 | hr | 1476 | 1177 | 3694 | 0.3188 | -0.1349 |